XML 25 R14.htm IDEA: XBRL DOCUMENT v3.26.1
Note 8 - Income Tax Provision
3 Months Ended
Mar. 31, 2026
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

Note 8.

Income Tax Provision

 

The Company uses the estimated effective tax rate ("ETR") method in computing the interim tax provision. Certain items, including those deemed unusual, infrequent, or that cannot be reliably estimated, are treated as discrete items and excluded from the estimated annual ETR ("AETR"). In these cases, the actual tax expense or benefit is reported in the same period as the related item. Certain tax effects are also not reflected in the AETR, primarily certain changes in the realizability of deferred tax assets and uncertain tax positions and are recorded in the period in which the change occurs. The AETR is revised, as necessary, at the end of successive interim reporting periods.  

 

The Company's effective income tax rate was 22.2% for the three months ended March 31, 2026, compared with 14.0% for the same period in 2025. The change in the ETR for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was due to the relationship of taxable income to consolidated pre-tax income (loss). The ETR differs for the three months ended March 31, 2026 from the full year-ended December 31, 2025 ETR of 28.8% due to the prior year changes in valuation allowance and prior period adjustments. 

 

The Company is required to evaluate the recoverability of its deferred tax assets and establish a valuation allowance, if necessary, to reduce its deferred tax asset to an amount that is more likely than not to be realizable. Considerable judgment and the use of estimates are required when determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. When evaluating the need for a valuation allowance, the Company considers many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies the Company would employ to avoid a tax benefit from expiring unused.

 

As of March 31, 2026, based on all available evidence, we concluded that a valuation allowance should remain on a portion of the deferred tax asset related to capital loss carryforwards that are not more-likely-than-not to be realized. For the three months ended March 31, 2026, the Company did not record an increase to the valuation allowance associated with capital loss carryforwards. At March 31, 2026, and December 31, 2025, the Company has recorded a total valuation allowance of approximately $309,000 and $309,000, respectively, associated with the life insurance net operating losses subject to limitations under IRC section 382 and capital loss carryforwards.